Theranos phenomenon: promises and fallacies

Area of Science:

• Medical Diagnostics
• Health Technology Assessment
• Public Health

Background:

• Advances in diagnostic technologies and genomics enable widespread testing of asymptomatic individuals.
• Commercial entities like Theranos propose revolutionary multi-analyte testing at low costs, challenging traditional diagnostic models.
• The potential for early disease detection through widespread testing offers opportunities for preventative and therapeutic interventions.

Purpose of the Study:

• To critically analyze Theranos's technology and claims.
• To contrast Theranos's promises with current diagnostic technologies.
• To highlight potential harms associated with widespread testing, self-testing, and over-medicalization.

Main Methods:

• Comparative analysis of Theranos's technology and claims against established diagnostic methods.
• Review of scientific literature and industry reports on diagnostic technologies.
• Ethical and public health considerations of new diagnostic paradigms.

Main Results:

• Most of Theranos's claims regarding their diagnostic technology appear to be exaggerated when compared to current standards.
• The potential benefits of widespread testing must be weighed against significant risks.
• Issues such as self-testing, self-interpretation, over-testing, over-diagnosis, and over-treatment pose considerable harms.

Conclusions:

• The revolutionary potential of Theranos's diagnostic technology is questionable.
• There is a need to balance enthusiasm for new diagnostic advances with a thorough understanding of associated risks and harms.
• Public health strategies must address the potential negative consequences of over-medicalization driven by new diagnostic capabilities.